Intra-lesional rF-B7.1 [vaccine; ALVAC CEA] versus rF-tricom vaccine in the treatment of metastatic cancer
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2015
At a glance
- Drugs ALVAC CEA (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Apr 2010 Actual end date added to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.